This Week on Drug Topics: March 1 to 5
Here’s a preview of the featured content to watch for this week on Drug Topics®.
Coronavirus Research News
With an estimated 70.5 million coronavirus disease 2019 (COVID-19) vaccine doses administered in the US as of this article’s press time, keeping up with pandemic news is more important than ever. Check back to Drug Topics® to stay informed on the latest coronavirus-related news and research.
Read more coronavirus-related news.
Medical World News Updates
In an interview with Drug Topics®, Colin Banas, chief medical officer at DrFirst, illuminated the key issues surrounding the upcoming deadline for the information blocking rule, a component of the 21st century Cures Act, and its impact on community pharmacies.
Over the Counter: New Podcast Episode
Don’t miss our upcoming Over the Counter episode with Drew Hegi and Bob Graul of First Financial Bank. Hegi and Graul are seasoned experts in pharmacy lending and spoke with Drug Topics® about what it takes to succeed in pharmacy ownership.
Listen to more podcast episodes.
Upcoming Webinar on Integrating CBD Into Your Pharmacy
This Wednesday, don’t miss our webinar with Chris Howard, VP, general counsel and chief compliance officer, and Mike Sullivan, director, trade marketing of E-Alternative Solutions, who will be joining Drug Topics® for this 1-hour webinar to address these concerns and equip you with the knowledge to effectively navigate the CBD industry.
Drug Topics® Journal, March 2021 Digital Edition
The March 2021 digital edition of Drug Topics Journal will soon be available on DrugTopics.com. In this issue, pharmacists offer advice on how to approach complementary and integrative therapies, and our cover story, in celebration of Women’s History Month, highlights the achievements from women in pharmacy practice.
Read more Drug Topics Journal issues.
In Case You Missed It: Examining Potential Mechanisms of Comorbid Bipolar Disorder and Migraine
In a systematic review, investigators aim to understand the mechanisms for comorbid bipolar disorder and migraine, as well as therapeutic targets.
